A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

Exclusion Criteria

• •1. Participants who require continuous use of proton pump inhibitors (PPIs) or histamine-2 (H2) receptor antagonists and participants who are taking PPIs within 5 days before the first dose of study drug.
• •2. Treatment with clinically significant enzyme inducers, such as phenytoin, carbamazepine, phenobarbital, rifampin, rifabutin, rifapentine, or Saint John's wort within 14 days before the first dose of study drug.
• •3. Treatment with any systemic anticancer treatment (including investigational products) within 30 days or 5 half-lives, whichever is shorter, before the first dose of study drug.
• •4. History of any of the following within the last 3 months before administration of the first dose of study drug:
• •* Ischemic myocardial event including angina requiring therapy and artery revascularization procedures, myocardial infarction, and unstable symptomatic ischemic heart disease.
• •* Ischemic cerebrovascular event, including transient ischemic attack and artery, revascularization procedures.
• •* Significant, uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia).
• •* New York Heart Association Class III to IV heart failure.
• •* Any other cardiac condition that, in the opinion of the investigator, could pose an additional risk for participation in the study (example, pericardial effusion or restrictive cardiomyopathy).
• •* Baseline prolongation of the QT interval corrected for heart rate (HR) using Fridericia's formula \[QT interval corrected for heart rate using Fridericia's formula (QTcF); example, repeated demonstration of QTcF interval \>480 millisecond (ms), history of congenital long QT syndrome, or torsades de pointes\].
• •5. Hypertension that is unstable or not controlled by medication.
• •6. History of uncontrolled brain metastasis unless:
• •* Previously treated with surgery, whole-brain radiation, or stereotactic radiosurgery, and
• •* Stable disease (SD) for \>=30 days, without steroid use (or stable steroid dose established for \>=14 days before the first dose of TAK-931).
• •7. Known history of human immunodeficiency virus infection.
• •8. Known hepatitis B virus (HBV) surface antigen seropositive or detectable hepatitis C virus (HCV) infection viral load. Note: Participants who have positive HBV core antibody or HBV surface antigen antibody can be enrolled but must have an undetectable HBV viral load.
• •9. Prior treatment with radiation therapy involving \>=25% of the hematopoietically active bone marrow within 3 months before the first dose of study drug.
• •10. Participants with known microsatellite instability-high (MSI-H) genotype or known wild type tumor protein 53 (TP53) per local testing.
• •11. Western Safety Cohort Only: Participants with Japanese heredity.